Case Report | |
Uterine Leiomyosarcoma: A Case Report | |
Forough Forghani1, Abolfazl Mehdizadeh Kashi2, Kambiz Sadegi3,4, Mania Kaveh2,1, Mehrangiz Ghafari5 | |
1Department of Obstetrics and Gynecology, Zabol University of Medical Sciences, Zabol, Iran 2Endometriosis and Gynecological Disorders Research Center, Iran University of Medical Sciences, Tehran, Iran 3Pain Research Center, Iran University of Medical Sciences, Tehran, Iran 4Department of Anesthesiology, Zabol University of Medical Sciences, Zabol, Iran 5Department of Pathology, Zabol University of Medical Sciences, Zabol, Iran |
|
IJWHR 2018; 6: 223-225 DOI: 10.15296/ijwhr.2018.38 Viewed : 3325 times Downloaded : 3436 times. Keywords : Uterine leiomyosarcoma, Gynecologic oncologist |
|
Full Text(PDF) | Related Articles | |
Abstract | |
Introduction: Uterine leiomyosarcoma (LMS) is a rare cancer originated from smooth muscle lining the walls of the uterus. LMS is known as an aggressive tumor with high mortality and morbidity rates as compared to other uterine cancers, despite the disease stage at the time of diagnosis. In most cases, LMS has been misdiagnosed as a benign uterine leiomyoma following hysterectomy or myomectomy. Case Presentation: We presented a 53-year-old G7 L7 woman who had referred to GYN clinic in Amir-al-Momenin hospital for abnormal uterine bleeding (AUB) for 6 months. On physical examination, we found an abdominal mass that had grown rapidly in the last 4 months. The computed tomography (CT) scan results showed a heterogeneous mass extending from the epigastric region to the pelvic area. Following an exploratory laparotomy, histopathology report confirmed the diagnosis of LMS. Her uterus, Fallopian tubes and ovaries were removed during a surgery, and she was referred to a gynecologic oncologist for possible chemotherapy. Conclusion: We found that the surgery is the only treatment for LMS; however, there is a little possibility to diagnose LMS before surgery in the patient with uncertain diagnosis and suspicious of LMS. Analysis of LDH and LDH3 levels along with dynamic diethylenetriaminepentaacetic acid (Gd-DTPA) enhanced, and MRI are recommended. |
Cite By, Google Scholar